EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
EDAP TMS SA (Nasdaq: EDAP) will release its financial results for Q4 and full-year 2023 on March 27, 2024. The company, a leader in robotic energy-based therapies, will host a conference call and webcast with top executives. Details for participation are provided.
03/13/2024 - 07:00 AM
Company to host conference call and webcast on Wednesday, March 27 th at 8:30am EDT
LYON, France, March 13, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th , 2024.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com , us.hifu-prostate.com and www.focalone.com .
Company Contact
Investor Contact jfraunces@lifesciadvisors.com
EDAP TMS SA will release its financial results for Q4 and full-year 2023 on March 27, 2024.
The conference call and webcast for EDAP TMS SA will be conducted by Ryan Rhodes (CEO), Ken Mobeck (CFO), and François Dietsch (CAO).
The conference call details are as follows: Date - March 27, 2024, Time - 8:30 am EDT, Domestic number - 1-877-451-6152, International number - 1-201-389-0879, Passcode - 13744102.
The webcast for EDAP TMS SA's conference call can be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1653981&tp_key=0c7b100f3f.
EDAP Rankings
#3917 Ranked by Stock Gains
EDAP Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
About EDAP
global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke
